Executive interview – Kane Biotech

Executive interview – Kane Biotech

Kane Biotech (TSX-V: KNE, OTCQB: KNBIF) is taking a unique approach to addressing human and animal health by developing technology to break up biofilms, the glue-like substance secreted by microorganisms that prevent their removal. Biofilms are implicated in a range of health concerns from periodontal disease, medical device-associated infections, hospital-acquired infections and food safety.


You may also be interested in these:

TMT

IP Group - executive interview

Investment Companies

Oakley Capital Investments – executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free